Abstract. – OBJECTIVE: Psychological distress caused by the SARS-CoV-2 outbreak has had deleterious effects on patients with chronic rheumatic disease, as those patients were highly susceptible for COVID-19 infection due to their chronicity, in addition to use of immunosuppressive drugs. Therefore, they underwent to more isolation than other people and develop more stress and depression. This study aimed at evaluating level of depression, anxiety, stress symptoms and physical health status in Egyptian patients with various rheumatic diseases during COVID-19 pandemic.

PATIENTS AND METHODS: This is a cross-sectional study conducted in Gharbia Governorate, Egypt. It included 440 diagnosed cases of rheumatic diseases from 1st to the end of March 2021. Depression, Anxiety and Stress Scale-21 (DASS21) and RAPID3/MDHAQ test were used to assess the pandemic’s psychological and functional effect on participants.

RESULTS: RAPID3 test results showed that during the COVID-19 outbreak the 40% of patients had a moderate severity functional affection and 20% had high severity. DASS21 depression scoring showed mild to moderate depression (33% and 35%, respectively), while severe depression was detected in only 3.2% of cases. Moderate anxiety was reported in 49% of cases, 29% had severe anxiety while 1% showed extremely severe anxiety. Female and cases aged more than 45 years had significantly more severe functional affection recorded by RAPID3 test, moderate stress and severe anxiety. On the other hand, severe depression was significantly higher in male and young patients younger than 45 years old.

CONCLUSIONS: Rheumatic disease patients have been highly susceptible to functional affection and psychological distress related to COVID-19 pandemic. Planning and implementation of programs to enforce coping strategies for these patients are required.

Key Words: Rheumatoid arthritis (RA), COVID-19, Routine assessment of patient index data 3 (RAPID3), Depression, Anxiety, Stress scale (DASS21).

Introduction

Coronavirus pandemic (COVID-19) is an extreme health, economic and social emergency, with at least 3,023,788 of confirmed cases worldwide. The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), started in Wuhan, China, at the beginning of December 2019, and the World Health Organization defined it as pandemic on 11 March 2020.

The COVID-19 pandemic led to people distancing, isolation, health and economic problems and harmful spread of false information. People, in particular patients and health professionals, have been under a great mental pressure.
that might have led to short- and long-term psychological diseases like stress, anxiety, apprehension, depression and post-traumatic stress disorders4-5.

Rheumatic diseases patients are those suffering from rheumatoid arthritis, lupus, scleroderma, Sjogren’s disease, gout, psoriatic arthritis, spondyloarthropathies, inflammatory myositis, fibromyalgia, or others. The chronic nature of this disease, the use of glucocorticoids at high doses, the high susceptibility to infections, the long hospitalization, and the brain affection by inflammation, put these patients at higher risk of developing associated psychiatric diseases. Some studies6 reported a prevalence of anxiety and depression up to 40% among these patients.

Rheumatic diseases patients are highly susceptible for developing COVID-19 infection due to their chronicity in addition to the use of immunosuppressive drugs, but they have also been facing many problems, like decreased drug availability, issues in reaching health services, and risks of physical inactivity resulting from staying at home. All these quarantine related problems may produce depression, anxiety, and general psychological distress among those patients7.

This cross-sectional study aimed at detecting the level of depression, anxiety and stress symptoms along with physical function impairment among patients with various rheumatic diseases during COVID-19 pandemic.

Patients and Methods

Study Design and Sample

This represents a cross-sectional study conducted in Gharbia Governorate, Egypt. It included all accessible rheumatic disease patients treated in Rheumatology, Rehabilitation & Physical Medicine Department, at Tanta University. The sample size was 384, it was calculated using Epi-Info program of statistics version 7.1.5.2 at confidence level 95% and confidence limits 5%. Cases were recruited from the 1st to the end of March 2021; for a better accuracy and validity, 440 cases were included in the study.

Inclusion criteria: rheumatic disease patients, diagnosed according to the European League Against Rheumatism (EULAR) classification criteria of each disease.

Exclusion criteria: non-rheumatic disease patients.

Data Collection and Instruments

A semi-structured pre-tested questionnaire was used for data collection and developed based on the associated reviews of literature and statistical experts in the medical college who assessed its validity and reliability. The questionnaire was translated into Arabic language and checked for completeness and consistency. Also, it was field-tested on a pilot sample of 38 cases (10% of the target sample) to clarify any ambiguities and to ensure a proper understanding of the questionnaire. Some modifications were added after pilot testing, to achieve higher internal consistency and reliability (Cronbach’s α = 0.82). The pilot sample was not included in the final results of the study. The questionnaire was built on Google form; social networks were used to distribute it among rheumatic disease patients. It consisted of three sections: sociodemographic data, DASS-21 and RAPID3 test.

Section One

This section focused on participants’ sociodemographic characteristics including gender, age, education, marital status, residence and income.

Section Two: DASS-21

COVID-19 distress index was calculated using Depression, Anxiety and Stress Scale-21 items (DASS-21). DASS-21 is a set of three self-report scales measures the emotional states of depression, anxiety and stress. Each of the three DASS-21 scales contains seven questions, divided into subscales with similar content.

Scoring: each item has four answers (never = 0, rarely = 1, sometimes = 2, most of the time = 3), and the whole scoring rang is 0-63.

The depression scale measures discomfort (lack of satisfaction), despair, life devaluation, self-deprecation and ignorance/lack of involvement and disable. The anxiety scale measures autonomic arousal, effects appeared on skeletal muscles, situational confusion and self-experiencing the effect of anxiety. The stress scale measures levels of chronic nonspecific arousal (wakefulness), difficulties in relaxation, nervous stimulation, being easily upset/confused, irritable/over-reactive and impatient.

Scores were calculated by summation for the relevant items. The DASS-21 was based on a dimensional rather than a categorical conception of psychological disorder.

Recommended cut-off scores for depression are: normal = 0-9, mild = 10-13, moderate =
COVID-19 effects on Egyptian rheumatic diseases patients

14-29, severe = 21-27 and extremely severe = 28+; anxiety scores are: normal = 0-7, mild: 8-9, moderate = 10-14, severe = 15-19, and extremely severe = 20+; stress scores are: normal = 0-14, mild = 15-18, moderate = 19-25, severe = 26-33 and extremely severe = 34+.

Section Three: RAPID3 Test
It is a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) which includes 0-10 scores for physical function (in 10 activities), a pain, and a PGA (on 0-10 visual analogue scales VAS), for a total score range between 0 and 30, where Near Remission (NR): 1-3, Low Severity (LS): 4-6, Moderate Severity (MS): 7-12, High Severity (HS): 13-30.

RAPID3 is a clinical index that demonstrates how is the patient affected in his/her multiple contexts of life. It guides the physicians to determine the right time to change medications, for providing better management of the disease. Compared to other indexes, it results to have an advantage in clinical practice, since it considers pain and focuses on the patient’s capacity to perform daily activities.

Statistical Analysis
The collected data were organized, tabulated and analysed using SPSS version 21 (Statistical Package for Social Sciences; IBM Corp., Armonk, NY, USA). Qualitative data were summarized as number and percentage and compared using Chi-square to test hypotheses. Quantitative data were presented as mean and standard deviation. The level of significance of p-value was 5%.

Results
The study included 440 participants with various rheumatic diseases. 82% of them were aged more than 45 years with a mean age of 40.75 ± 14.12. Most participants were female 76.6%, of which married 58.9%, and 72.7% with a high education level. More than half of participants had enough and saving income (54.8%), of which the majority (77.3%) were urban resident. Regarding rheumatic disease type, 25.5% had osteoarthritis, 20.5% Rheumatoid arthritis, 1.8% Lupus, while other diseases represented 53.3% of the patients. Most of the cases (79.5%) were taking non-steroidal anti-inflammatory drugs (NSAID), while 34.1%, 11.4%, 11.4% were on conventional DMARDs, biological DMARDs and steroids, respectively.

Among the studied cases, RAPID3 test result mean was 12.59 ± 6.05, less than half of cases (40%) had moderate severity affection and 20% had high severity, as shown in Figure 1. Significantly high severity RAPID3 scores were detected in female (21.7%), aged more than 45 years (34.4%), with lower education (42.5% with a level lower than secondary school), widow (44.4%), and low-income patients (32.5%) (Table I).

The result of DASS21 scoring in the study population had mean 35.85 ± 13.45 (range 2-63, median was 34.0). Regarding depression, most of the studied patients showed mild to moderate depression (33.0% and 35%, respectively), while severe depression was detected in only 3.2% of the cases (Figure 2). Severe depression was significantly higher in male (5.8%), patients younger than 45 years, rural resident, divorced, widow and low-income patients (3.6%, 4%, 13.8%, 11.1% and 10.4%, respectively) (Table II).

Concerning anxiety, severe anxiety was reported in 29% of cases and 1% showed extremely severe anxiety, while the majority showed moderate anxiety (49%) (Figure 3). Severe anxiety was more significantly detected to be in female (30.3%), older than 45 years (33.1%), with a high school education level (higher than secondary school - 32.5%), urban resident (34.4%) and divorced (44.8%), while 11.1% of widow showed extremely severe anxiety (Table III).

Figure 1. RAPID3 test scoring in the study population.
Stress scale results showed normal scoring in about two thirds of the cases (67%). Nearly equal percentage showed mild to moderate stress (17% and 16%, respectively) (Figure 4). Moderate stress was significantly higher in females (18.1%), older than 45 years (25.6%), with a lower level of education (20.8% under secondary school), urban resident (17.1%), widows (44.4%) and low-income cases (39.0%) (Table IV).

Discussion

During COVID-19 pandemic, in addition to the infection itself, many factors affected the general population, such as social isolation, quarantine, loneliness and fear of infection or death. The apprehension that occurred is a usual response to any major life-threatening event, and when a chronic illness is present, this change might become harmful and may lead to psychiatric illness.11,12

Psychiatric disorders such as anxiety, depression, and stress can often be detected in patients with rheumatic diseases and can negatively affect their quality of life. However, psychiatric symptoms may differ in patients suffering from these diseases, and the prevalence of psychiatric symptoms can vary.13,14

It has been shown16,17 that patients suffering from chronic rheumatic diseases have been among the most vulnerable to the traumatic stress...
due to the COVID-19 pandemic lockdown. They are also immune deficient, feel intense fear of being more susceptible to the SARS-CoV-2 infection; this new type of apprehension may further initiate psychological diseases\(^9\).

In the present study, RAPID3 test mean was $12.59 \pm 6.05$, less than half of cases (40%) had a moderate severity affection, while 20% showed high severity. This was in lower percentage compared with Boone et al\(^19\), who evaluated the routine practice of rheumatoid arthritis patients treated with anti-rheumatic drugs (b-DMARDs). They reported near average figures ($11.7 \pm 6.2$), but 96% of the patients had a moderate-to-high RAPID3 score. The higher percentage in his study may be attributed to the sample criteria which included only rheumatoid arthritis patients all of them on biological (DMARDs), second line of treatment which also indicated a more severe disease.

The result of DASS21 anxiety score showed severe anxiety in 29% of cases and 1% had extremely severe anxiety while the majority had moderate anxiety (49%). This finding is higher in degree if compared with another study\(^20\) investigating the psychological health and associated factors among rheumatoid arthritis Filipinos during COVID-19 pandemic, which reported that about one third of patients had moderate to severe anxiety (38.7%). This higher severity score in the present study may be due to our sample criteria, as our sample included different rheumatic

\begin{table}
\centering
\caption{DASS21 depression scoring, according to the socio-demographic characteristics of the study population.}
\begin{tabular}{|c|c|c|c|c|c|c|}
\hline
 & \textbf{Normal} & \textbf{Mild depression} & \textbf{Moderate depression} & \textbf{Severe depression} & \textbf{Total} & \textbf{$\chi^2$/$p$} \\
 & \textbf{129 (29.3)} & \textbf{145 (33.0)} & \textbf{152 (34.5)} & \textbf{14 (3.2)} & \textbf{440 (100.0)} & \\
\hline
\textbf{Gender} & & & & & & \\
\textbf{Male} & 44 (42.7) & 40 (38.8) & 13 (12.6) & 6 (5.8) & 103 (100.0) & 0.000* \\
\textbf{Female} & 85 (25.2) & 105 (31.2) & 139 (41.2) & 8 (2.4) & 337 (100.0) & 0.000* \\
\hline
\textbf{Age group} & & & & & & \\
\textbf{≤ 45 years} & 79 (28.2) & 117 (41.8) & 74 (26.4) & 10 (3.6) & 280 (100.0) & 0.000* \\
\textbf{> 45 years} & 50 (31.3) & 28 (17.5) & 78 (48.8) & 4 (2.5) & 160 (100.0) & 0.000* \\
\hline
\textbf{Education} & & & & & & \\
\textbf{≤ 2ry school} & 53 (44.2) & 25 (20.8) & 38 (31.7) & 4 (3.3) & 120 (100.0) & 0.000* \\
\textbf{> 2ry school} & 76 (23.8) & 120 (37.5) & 114 (35.6) & 10 (3.1) & 320 (100.0) & 0.000* \\
\hline
\textbf{Residence} & & & & & & \\
\textbf{Urban} & 73 (21.5) & 121 (35.6) & 136 (40.0) & 10 (2.9) & 340 (100.0) & 0.000* \\
\textbf{Rural} & 56 (36.0) & 24 (24.0) & 16 (16.0) & 4 (4.0) & 100 (100.0) & 0.000* \\
\hline
\textbf{Marital status} & & & & & & \\
\textbf{Single} & 34 (29.3) & 42 (36.2) & 34 (29.3) & 6 (5.2) & 116 (100.0) & 0.000* \\
\textbf{Married} & 79 (30.5) & 91 (35.1) & 89 (34.4) & 0 (0.0) & 259 (100.0) & 0.000* \\
\textbf{Divorced} & 8 (27.6) & 8 (27.6) & 9 (31.0) & 4 (13.8) & 29 (100.0) & 0.000* \\
\textbf{Widow} & 8 (22.2) & 4 (11.1) & 20 (55.6) & 4 (11.1) & 36 (100.0) & 0.000* \\
\hline
\textbf{Income} & & & & & & \\
\textbf{Not enough} & 31 (40.3) & 16 (20.8) & 22 (28.6) & 8 (10.4) & 77 (100.0) & 0.000* \\
\textbf{Just Enough} & 58 (24.1) & 75 (31.1) & 102 (42.3) & 6 (2.5) & 241 (100.0) & 0.000* \\
\textbf{Enough and saving} & 40 (32.8) & 54 (44.3) & 28 (23.0) & 0 (0.0) & 122 (100.0) & 0.000* \\
\hline
\end{tabular}
\textsuperscript*x} Chi square test; *significant at $p = 0.05$.
diseases, while other study sample included only rheumatoid arthritis and lupus erythematosus patients.

Concerning DASS21 depression score, the present study population showed mild-to-moderate depression (33.0% and 35%, respectively), while severe depression was detected in 3.2% of cases. This was higher than that reported in Filipinos study\textsuperscript{20}, where moderate-to-high severe depression was reported in 27.7% of cases.

Some researchers\textsuperscript{21,22} explained the cause of increasing anxiety as psychological stress result in high production of inflammatory cytokines in the brain (IL-6, IL-1B), which are responsible for the initiation of anxiety and depression. Central catecholamine stimulates the release of IL-1B, which initiates microglia activation and monocytes attraction into the brain. These events lead to psychological diseases.

Regarding DASS21 stress score in the present study, normal stress score was detected in about two third of cases (67%). Nearly equal percent of cases had mild-to-moderate stress (17% and 16%, respectively), which come nearly similar to another study\textsuperscript{20} which reported moderate to severe stress symptoms in 12.3% of the Filipinos patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus.

On the other hand, in Egyptian study\textsuperscript{23} to evaluate impact of COVID-19 pandemic on rheumatic diseases patients resulted in no difference in anxiety and depression levels between rheumatic diseases cases and healthy controls, and conclud-
ed that similar degrees of anxiety and depression were felt by rheumatic diseases cases as well as by the general population during the pandemic\textsuperscript{23}.

These results showed that, in chronic rheumatic diseased patients, psychological health issues highly increased due to the stressful COVID-19 situation, therefore, psychological support for those patients is needed in order to empower them, increase their endurance, and avoid over-thinking about their own risks of infection. Telemedicine and tele-assistance are effective methods that can be adopted and implemented\textsuperscript{24}. Telemedicine can reduce the risk of patients’ exposure to infection, keep the disease under control and reassure the patient; thus, potentially decreasing anxious and depressive symptoms\textsuperscript{25}.

Limitations

One limitation of this study represented by the fact that the study is totally based on a questionnaire, which considered patients’ health status, mood, and perceptions at the only time of study.

Conclusions

During COVID-19 lockdown, chronic rheumatic diseases patients presented a high level of depression, anxiety, and stress symptoms, also moderate-to-high severity limitation of physical function, which negatively affected the rheumatic disease outcomes. Planned intervention should be performed to reduce mental health problems, and to overcome the disease worsening in this vulnerable population.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Acknowledgements

The authors would like to thank the Deanship of Scientific Research, Majmaah University, Kingdom of Saudi Arabia, for research support under the project number: R-2022-144

Ethical Approval

The study protocol was approved by the Ethics Committee of Tanta University (ref. No. JYDLL2020002).

Informed Consent

Informed online consent has been obtained through the first item of the questionnaire. All data were confidential and used only for the study purposes.
Authors’ Contribution
All authors contributed to the study conception and design, material preparation, data collection and analysis were performed by Hala Mostafa Elsabagh, Radwa Mostafa El Khouly, Marwa A. Abo El Hawa. The first draft of the manuscript was written by Hala Mostafa Elsabagh and Amira A. R. Moawad, all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

ORCID ID
Hala Mostafa Elsabagh: https://orcid.org/0000-0002-4975-3594; Amira Ahmed Moawad: 0000-0001-5894-6585.

References
1) Hoof DE Van. Lockdown is the world’s biggest psychological experiment - and we will pay the price. World Econ Forum [Internet] 2020; 9: 1-5. Available from: https://www.weforum.org/agenda/2020/04/this-is-the-psychological-side-of-the-covid-19-pandemic-that-were-ignoring/.
3) WHO Director-General’s opening remarks at the media briefing on COVID-19, March 2020.
11) Pincus T, Skummer PT, Grisanti MT, Castrellon I, Yazici Y. MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter. Bull NYU Hosp Jt Dis 2012; 70: 177-186.

